Omfurn India Fund Raise of ₹28.01 Cr

Omfurn India H1 FY27 Results: Net Profit ₹2.5 Cr, Up 13.6% YoY

Omfurn India Ltd reported revenue from operations of ₹48.6 Cr (+47.3% YoY) and net profit of ₹2.5 Cr (+13.6% YoY) for H1 FY27.

Key figure

Net profit ₹2.5 Cr · +13.6% YoY

Omfurn India Other Announcement

Omfurn India Limited filed its Regulation 74(5) compliance certificate for the quarter ended 30th September, 2026.

Omfurn India Annual General Meeting

Omfurn India Limited conducted its 29th Annual General Meeting on September 22, 2026, approving resolutions including financial statements and director remuneration revisions.

Omfurn India Other Announcement

Omfurn India Limited has issued a letter to shareholders providing the web-link to access the Annual Report 2025-26 and the Notice of the 29th AGM.

Omfurn India Annual General Meeting

Omfurn India Limited has issued a notice for its 29th Annual General Meeting scheduled for September 22, 2026, to transact ordinary and special business.

Omfurn India Bags ₹38.88 Cr Order

Omfurn India Limited secured various orders worth ₹38.88 Crore from Oberoi Realty Limited and its subsidiary. The projects involve supplying pre-finished wooden doors and installation.

Value

₹38.88 Cr

Execution

By December 31, 2026

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.

Gujarat Inject (Kerala) Fund Raise of ₹3 Cr

Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.

Value

₹3.00 Cr